<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>81</volume><submitter>Wang JC</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>With life expectancy for people living with HIV (PLWH) approaching that of the general population, age-related conditions like osteoporosis are increasingly common. Both HIV infection and long-term antiretroviral therapy (ART), particularly tenofovir disoproxil fumarate (TDF), are associated with early-onset osteoporosis. Bisphosphonates are commonly used for treatment, but the optimal strategy for improving bone health in PLWH remains unclear.&lt;h4>Methods&lt;/h4>We conducted a network meta-analysis (NMA) with component analysis of randomized controlled trials (RCTs) identified from Medline, EMBASE, Cochrane CENTRAL, Scopus, Web of Science and CINAHL EBSCO databases, from inception to December 1, 2024. The study included RCTs comparing zoledronate, alendronate, calcium and v</pubmed_abstract><journal>EClinicalMedicine</journal><pagination>103103</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11876934</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials.</pubmed_title><pmcid>PMC11876934</pmcid><pubmed_authors>Chang YF</pubmed_authors><pubmed_authors>Tu YK</pubmed_authors><pubmed_authors>Fang CJ</pubmed_authors><pubmed_authors>Kuan FC</pubmed_authors><pubmed_authors>Lai PC</pubmed_authors><pubmed_authors>Li CW</pubmed_authors><pubmed_authors>Chung SM</pubmed_authors><pubmed_authors>Hsu KL</pubmed_authors><pubmed_authors>Chen PL</pubmed_authors><pubmed_authors>Wang JC</pubmed_authors><pubmed_authors>Wu CH</pubmed_authors><pubmed_authors>Wu PT</pubmed_authors><pubmed_authors>Tai TW</pubmed_authors><pubmed_authors>Shih CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials.</name><description>&lt;h4>Background&lt;/h4>With life expectancy for people living with HIV (PLWH) approaching that of the general population, age-related conditions like osteoporosis are increasingly common. Both HIV infection and long-term antiretroviral therapy (ART), particularly tenofovir disoproxil fumarate (TDF), are associated with early-onset osteoporosis. Bisphosphonates are commonly used for treatment, but the optimal strategy for improving bone health in PLWH remains unclear.&lt;h4>Methods&lt;/h4>We conducted a network meta-analysis (NMA) with component analysis of randomized controlled trials (RCTs) identified from Medline, EMBASE, Cochrane CENTRAL, Scopus, Web of Science and CINAHL EBSCO databases, from inception to December 1, 2024. The study included RCTs comparing zoledronate, alendronate, calcium and v</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-04-04T19:26:58.052Z</modification><creation>2025-04-04T19:26:58.052Z</creation></dates><accession>S-EPMC11876934</accession><cross_references><pubmed>40040862</pubmed><doi>10.1016/j.eclinm.2025.103103</doi></cross_references></HashMap>